{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T05:54:45Z","timestamp":1773554085450,"version":"3.50.1"},"reference-count":0,"publisher":"International Institute of Anticancer Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CDP"],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:p>Background\/Aim: The present study utilized the three-dimensional histoculture drug response assay (HDRA) to determine the efficacy of recombinant methioninase (rMETase) on tumor tissue resected from patients with late-stage cancer, as a functional biomarker of sensitivity to methionine restriction therapy. Patients and Methods: Resected peritoneal-metastatic cancer, including colorectal cancer, pancreatic cancer, ovarian cancer, and pseudomyxoma were placed on Gelform in RPMI 1640 medium for seven days and treated with rMETase from 2.5 U\/ml to 20 U\/ml. Cell viability was determined using the MTT assay. A total of 48 patients with late-stage cancer underwent testing for rMETase responsiveness using the HDRA. Results: Colorectal cancer and pseudomyxoma had the highest sensitivity to rMETase. Pancreatic and ovarian cancer also responded to rMETase, but to a lesser degree. Conclusion: Patients with tumors with at least 40% sensitivity to rMETase in the HDRA are being considered as candidates for methionine restriction therapy, which includes the use of rMETase in combination with a low-methionine diet.<\/jats:p>","DOI":"10.21873\/cdp.10314","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:59:45Z","timestamp":1715173185000},"page":"239-243","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Recombinant Methioninase on Late-stage Patient Cancer in the Histoculture Drug Response Assay (HDRA) as a Potential Functional Biomarker of Sensitivity to Methionine-restriction Therapy in the Clinic"],"prefix":"10.21873","volume":"4","author":[{"given":"YUTARO","family":"KUBOTA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MASATO","family":"SASAKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QINGHONG","family":"HAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHIHIRO","family":"HOZUMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAKUYA","family":"TSUNODA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERT M.","family":"HOFFMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"9336","published-online":{"date-parts":[[2024,5,3]]},"container-title":["Cancer Diagnosis &amp; Prognosis"],"original-title":[],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T12:59:54Z","timestamp":1715173194000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancerdiagnosisprognosis.org\/article\/334\/efficacy-of-recombinant-methioninase-on-late-stage-patient-cancer-in-the-histoculture-drug-response-assay-hdra-as-a-potential-functional-biomarker-of-sensitivity-to-methionine-restriction-therapy-in-the-clinic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,3]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.21873\/cdp.10314","relation":{},"ISSN":["2732-7787"],"issn-type":[{"value":"2732-7787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,3]]}}}